Summit Therapeutics SMMT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $132.62M-10.0% | $147.29M+12.4% | $131.1M-37.0% | $208.02M+306% | $51.27M-0.2% | ||
| $62.59M-19.4% | $77.63M-24.7% | $103.12M-71.4% | $360.42M+2,212% | $15.59M+9.5% | ||
| $195.21M-13.2% | $224.93M-4.0% | $234.21M-58.8% | $568.44M+750% | $66.85M+1.9% | ||
| $5.79M+0.6% | $5.75M+138% | $2.42M-11.4% | $2.73M-30.7% | $3.94M-10.9% | ||
| -$189.42M+13.6% | -$219.17M+5.4% | -$231.79M+59.0% | -$565.71M-799% | -$62.91M-2.8% | ||
| -$0.24+14.3% | -$0.28+9.7% | -$0.31+59.2% | -$0.76-744% | -$0.090.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Summit Therapeutics profitable?
- Summit Therapeutics is not currently profitable: it reported a net loss of $1.2B over the trailing twelve months, a -271685.0% net margin.
- What is Summit Therapeutics's earnings per share?
- Summit Therapeutics's diluted EPS over the trailing twelve months is $-1.59.
- Where does Summit Therapeutics's income statement data come from?
- Every line is extracted from Summit Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.